lilly semaglutide launches lower-price weight-loss drug without injector pen Doctor explains challenges to using

Starting July 1, 2026, Medicare will cover FDA-approved weight-loss medications like Wegovy (semaglutide) and Zepbound (tirzepatide) for a flat $50 per month through a new initiative called the Medicare GLP-1 Bridge Program

"Consumers' overall high satisfaction with these medications for weight loss has been tempered primarily by concerns about side effects, weight gain if discontinued, and cost," said Kathy Risch, SVP, Shopper Insights and Thought Leadership, Acosta Group

In aged animals, angiogenesis is reduced, resulting in poor wound healing

Those with health conditions or on medication should consult a healthcare provider before use